Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TV-1380 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| TV-1380 150 mg | EXPERIMENTAL | - |
| TV-1380 300 mg | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| TV-1380 150 mg | DRUG | Subjects assigned to TV-1380 150 mg will be administered one intra-muscular (IM) injection once weekly over 12 weeks. The injection volume will be the same for all treatment groups. Therefore, to accommodate the volume required for the highest dosing group (3.0 mL), subjects in this group will receive 3.0 mL IM injection of TV-1380 150 mg (1.5 mL TV-1380 and 1.5 mL placebo/diluents). |
| TV-1380 300 mg | DRUG | Subjects assigned to TV-1380 300 mg will be administered one intra-muscular (IM) injection once weekly over 12 weeks. Subjects in this treatment group will receive 3.0 mL TV-1380. |
| Placebo | DRUG | Subjects assigned to placebo will be administered one intra-muscular (IM) injection once weekly over 12 weeks. Subjects in this treatment group will receive 3.0 mL placebo. |
Inclusion Criteria: * Have the ability to understand, and having understood, provide written informed consent to comply with the treatment protocol. * Male or female aged 18-60 years (inclusive). * Meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. * Other criteria apply; p...
TV-1380 is an investigational small molecule being developed for the treatment of cocaine addiction. It is intended to facilitate abstinence in cocaine-dependent subjects. The drug is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
TV-1380 is being developed by Teva Pharmaceutical Industries Limited, a company publicly traded under the ticker symbol TEVA. The drug is currently in Phase 2 clinical development for the treatment of cocaine addiction.
TV-1380 is in Phase 2 clinical development. It is an investigational drug for the treatment of cocaine addiction and has not been approved by regulatory authorities. One Phase 2 clinical trial for TV-1380 has been completed.
TV-1380 has been studied in one completed Phase 2 clinical trial, identified as NCT01887366. This trial evaluated the efficacy and safety of TV-1380 as a treatment for facilitation of abstinence in cocaine-dependent subjects, enrolling 208 participants in the United States and Spain.
TV-1380 is the primary name for this investigational drug. No alternative names have been reported for this asset. It is being developed by Teva Pharmaceutical Industries Limited for the treatment of cocaine addiction.